126 related articles for article (PubMed ID: 16557022)
1. The predictive value of C-reactive protein in end-stage renal disease: is it clinically significant?
van der Sande FM; Kooman JP; Leunissen KM
Blood Purif; 2006; 24(4):335-41. PubMed ID: 16557022
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of C-reactive protein for heart disease in dialysis patients.
Wang AY
Curr Opin Investig Drugs; 2005 Sep; 6(9):879-86. PubMed ID: 16187687
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein and end-stage renal disease.
Lacson E; Levin NW
Semin Dial; 2004; 17(6):438-48. PubMed ID: 15660574
[TBL] [Abstract][Full Text] [Related]
4. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.
Snaedal S; Heimbürger O; Qureshi AR; Danielsson A; Wikström B; Fellström B; Fehrman-Ekholm I; Carrero JJ; Alvestrand A; Stenvinkel P; Bárány P
Am J Kidney Dis; 2009 Jun; 53(6):1024-33. PubMed ID: 19394732
[TBL] [Abstract][Full Text] [Related]
5. Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients.
Ashman N; Macey MG; Fan SL; Azam U; Yaqoob MM
Nephrol Dial Transplant; 2003 Oct; 18(10):2088-96. PubMed ID: 13679485
[TBL] [Abstract][Full Text] [Related]
6. Ceruloplasmin and acute phase protein levels are associated with cardiovascular disease in chronic dialysis patients.
Panichi V; Taccola D; Rizza GM; Consani C; Migliori M; Filippi C; Paoletti S; Sidoti A; Borracelli D; Panicucci E; Giovannini L
J Nephrol; 2004; 17(5):715-20. PubMed ID: 15593040
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients.
Panichi V; Taccola D; Rizza GM; Consani C; Ghiadoni L; Filippi C; Cristofani R; Panicucci E; Migliori M; Sidoti A; Biagioli M; Boracelli D; Barsotti G; Tetta C
Nephron Clin Pract; 2006; 102(2):c51-8. PubMed ID: 16224196
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients.
Kanwar M; Hashem M; Rosman H; Kamalakannan D; Cheema A; Ali A; Gardin J; Maciejko JJ
Am J Cardiol; 2006 Nov; 98(9):1283-7. PubMed ID: 17056347
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein in end-stage renal disease: are there reasons to measure it?
Stenvinkel P; Lindholm B
Blood Purif; 2005; 23(1):72-8. PubMed ID: 15627740
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Li JJ; Fang CH
Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
[TBL] [Abstract][Full Text] [Related]
11. Significance of albumin and C-reactive protein variations in 300 end stage renal disease patients in Tehran University of Medical Sciences Hospitals during year 2010.
Dashti N; Einollahi N; Nabatchian F; Moradi Sarabi M; Zarebavani M
Acta Med Iran; 2012; 50(3):197-202. PubMed ID: 22418989
[TBL] [Abstract][Full Text] [Related]
12. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.
Panichi V; Rizza GM; Paoletti S; Bigazzi R; Aloisi M; Barsotti G; Rindi P; Donati G; Antonelli A; Panicucci E; Tripepi G; Tetta C; Palla R;
Nephrol Dial Transplant; 2008 Jul; 23(7):2337-43. PubMed ID: 18305316
[TBL] [Abstract][Full Text] [Related]
13. Predictors of cardiovascular death in ESRD.
Zoccali C; Tripepi G; Mallamaci F
Semin Nephrol; 2005 Nov; 25(6):358-62. PubMed ID: 16298255
[TBL] [Abstract][Full Text] [Related]
14. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
[TBL] [Abstract][Full Text] [Related]
15. Measurement of circulating troponin Ic enhances the prognostic value of C-reactive protein in haemodialysis patients.
Boulier A; Jaussent I; Terrier N; Maurice F; Rivory JP; Chalabi L; Boularan AM; Delcourt C; Dupuy AM; Canaud B; Cristol JP
Nephrol Dial Transplant; 2004 Sep; 19(9):2313-8. PubMed ID: 15252159
[TBL] [Abstract][Full Text] [Related]
16. CRP has little incremental value over traditional cardiovascular risk factors in risk stratification.
Farkouh ME; Bansilal S; Mathew V
Nat Clin Pract Cardiovasc Med; 2007 Jun; 4(6):290-1. PubMed ID: 17522718
[No Abstract] [Full Text] [Related]
17. Association between periodontitis and systemic inflammation in patients with end-stage renal disease.
Nadeem M; Stephen L; Schubert C; Davids MR
SADJ; 2009 Nov; 64(10):470-3. PubMed ID: 20306866
[TBL] [Abstract][Full Text] [Related]
18. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Field KM
Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
[TBL] [Abstract][Full Text] [Related]
19. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease.
Breit SN; Carrero JJ; Tsai VW; Yagoutifam N; Luo W; Kuffner T; Bauskin AR; Wu L; Jiang L; Barany P; Heimburger O; Murikami MA; Apple FS; Marquis CP; Macia L; Lin S; Sainsbury A; Herzog H; Law M; Stenvinkel P; Brown DA
Nephrol Dial Transplant; 2012 Jan; 27(1):70-5. PubMed ID: 21940482
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
